Amgen's Xgeva data for prostate cancer excites analysts...

New Topic Post Reply Printable Version
[ << Previous Thread | Next Thread >> ]

Regular Member

Date Joined Jun 2010
Total Posts : 416
   Posted 12/15/2010 8:30 AM (GMT -6)   
Would appreciate any added info my fellow members may have on this drug..?
"Amgen shares have soared after the firm presented impressive late-stage data which shows that the jewel in its portfolio, denosumab significantly improved bone metastasis-free survival in men with prostate cancer compared to placebo."
At SOME POINT, one has to believe that each of the small victories can be combined to actually help some of us. I hope.
Good thoughts today to all of you1

Regular Member

Date Joined Aug 2010
Total Posts : 245
   Posted 12/15/2010 10:18 AM (GMT -6)   
BobCape:  I take note of breast cancer treatment info.  The drug was mentioned for treatment of bone mets from BC recently too.  Hope the following link helps you since it contains some stats...

Veteran Member

Date Joined Aug 2010
Total Posts : 644
   Posted 12/15/2010 6:25 PM (GMT -6)   
Here's some info:

BioDrugs. 2010 Dec 1;24(6):379-86. doi: 10.2165/11203310-000000000-00000.
Denosumab: in cancer treatment-induced bone loss.

Muir VJ, Scott LJ.

Adis, a Wolters Kluwer Business, Auckland, New Zealand.

Denosumab is a fully human monoclonal IgG(2) antibody that binds to receptor activator of nuclear factor-κB ligand (RANKL) and inhibits bone resorption due to RANKL-mediated osteoclastogenesis. In Europe, subcutaneous denosumab is indicated for cancer treatment-induced bone loss in men with prostate cancer and in postmenopausal women with breast cancer. In a large (n= 1468), well designed, multinational, phase III trial in adult patients with prostate cancer who were receiving androgen-deprivation therapy, bone mineral density (BMD) at the lumbar spine was significantly improved from baseline after 24 (primary endpoint) and 36 months of treatment with subcutaneous denosumab (60 mg once every 6 months), relative to that with placebo. Moreover, the risk of new vertebral fracture was significantly reduced by 62% in the denosumab group compared with the placebo group. In breast cancer patients receiving aromatase inhibitor therapy (n =252), subcutaneous denosumab (60 mg once every 6 months) significantly improved BMD at the lumbar spine from baseline after 12 (primary endpoint) and 24 months of treatment relative to placebo in a pivotal phase III trial. There were significant improvements in BMD at all skeletal sites, including the lumbar spine, total hip, and femoral neck, after 24 and 36 months' denosumab treatment in prostate cancer patients and after 12 and 24 months' treatment in breast cancer patients. In general, these improvements occurred irrespective of baseline characteristics, including age, duration of hormone ablation therapy, and baseline BMD. Denosumab treatment was generally well tolerated for up to 24 months in breast cancer patients and for up to 36 months in prostate cancer patients.

Here's a link to another journal article (free)

Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group.
N Engl J Med. 2009 Aug 20;361(8):745-55. Epub 2009 Aug 11.PMID: 19671656 [PubMed - indexed for MEDLINE]Free Article

Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C, Leder BZ, Goessl C.
J Urol. 2009 Dec;182(6):2670-5.PMID: 19836774 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

for these and more go to and type in "denosumab prostate" as the search phrase.
New Topic Post Reply Printable Version
Forum Information
Currently it is Saturday, September 22, 2018 10:38 AM (GMT -6)
There are a total of 3,005,668 posts in 329,249 threads.
View Active Threads

Who's Online
This forum has 161795 registered members. Please welcome our newest member, jjakefamily.
282 Guest(s), 12 Registered Member(s) are currently online.  Details
notsosicklygirl, logoslidat, pasayten, cashlessclay, jjakefamily, FamilyGuy, mareish, beatUC, Pixie415, MacroMan, rpgdancer, Shayanv